Erica Barnell, MD, PhD, of Washington University School of Medicine, and founder of Geneoscopy Inc, gives an update on the FDA approval of multitarget stool RNA test ColoSense.
Dr. Barnell discusses how the test can aid in public health initiatives, as well as the rise of colorectal cancer diagnoses in younger patients.
The test was approved based on the CRC-PREVENT study, which demonstrated its beneficial sensitivity and specificity rates in comparison to traditional colonoscopy.